GlassScriptPhysician profile
Fernando Norona
NPI 1164488128
$3,231.22
in general payments reported to CMS, 2019-2025
26 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $112 · 2021: $112 · 2022: $478 · 2023: $908 · 2024: $821 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $691.53 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $459.07 | 2023-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $447.74 | 2021-2025 | |
| Eisai INC. | $393.67 | 2021-2025 | |
| Lilly USA, LLC | $299.81 | 2020-2025 | Amyvid, Kisunla |
| Lundbeck LLC | $151.13 | 2023-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $109.50 | 2024-2025 | Rexulti |
| Argenx US, INC. | $90.91 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Amneal Pharmaceuticals LLC | $68.75 | 2020-2025 | Crexont |
| Pfizer INC. | $60.78 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.65 | 2022 | |
| Avion Pharmaceuticals | $47.21 | 2022-2023 | Dhivy |
| Impel Pharmaceuticals INC. | $40.54 | 2023 | Trudhesa |
| Nobelpharma America, LLC | $28.43 | 2025 | |
| Allergan, INC. | $27.03 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $24.55 | 2021 | |
| Acorda Therapeutics, INC | $23.24 | 2024 | Inbrija |
| Amgen INC. | $20.93 | 2020 | |
| Almirall LLC | $20.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.76 | 2020 | |
| Biogen, INC. | $18.21 | 2021 | |
| Upsher-Smith Laboratories LLC | $17.76 | 2021 | |
| Corium, LLC | $17.21 | 2023 | Adlarity |
| Mdd US Operations, LLC | $16.56 | 2019 | |
| Neurocrine Biosciences, INC. | $14.83 | 2020 | |
| C2n Diagnostics, LLC | $14.12 | 2025 | Precivityad2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Norona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.